A detailed history of Envestnet Asset Management Inc transactions in Compugen LTD stock. As of the latest transaction made, Envestnet Asset Management Inc holds 19,327 shares of CGEN stock, worth $29,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,327
Previous 21,808 11.38%
Holding current value
$29,183
Previous $36,000 5.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$1.56 - $2.1 $3,870 - $5,210
-2,481 Reduced 11.38%
19,327 $34,000
Q2 2024

Aug 08, 2024

SELL
$1.68 - $2.52 $2,978 - $4,467
-1,773 Reduced 7.52%
21,808 $36,000
Q1 2024

May 13, 2024

SELL
$1.75 - $2.95 $23,558 - $39,712
-13,462 Reduced 36.34%
23,581 $60,000
Q4 2023

Feb 13, 2024

SELL
$0.53 - $2.0 $2,828 - $10,674
-5,337 Reduced 12.59%
37,043 $73,000
Q3 2023

Nov 13, 2023

BUY
$0.88 - $1.31 $6,022 - $8,965
6,844 Added 19.26%
42,380 $39,000
Q2 2023

Aug 04, 2023

BUY
$0.57 - $1.38 $8,204 - $19,862
14,393 Added 68.07%
35,536 $40,000
Q1 2023

May 11, 2023

BUY
$0.68 - $1.11 $418 - $682
615 Added 3.0%
21,143 $14,000
Q4 2022

Feb 07, 2023

SELL
$0.58 - $1.2 $1,425 - $2,949
-2,458 Reduced 10.69%
20,528 $14,000
Q3 2022

Nov 10, 2022

BUY
$0.66 - $2.32 $2,978 - $10,470
4,513 Added 24.43%
22,986 $15,000
Q2 2022

Aug 03, 2022

SELL
$1.57 - $3.33 $23,215 - $49,240
-14,787 Reduced 44.46%
18,473 $34,000
Q1 2022

May 04, 2022

BUY
$2.76 - $4.64 $17,385 - $29,227
6,299 Added 23.36%
33,260 $111,000
Q4 2021

Feb 04, 2022

BUY
$4.09 - $7.16 $8,237 - $14,420
2,014 Added 8.07%
26,961 $116,000
Q3 2021

Oct 07, 2021

BUY
$5.8 - $8.02 $84,703 - $117,124
14,604 Added 141.2%
24,947 $149,000
Q2 2021

Aug 04, 2021

BUY
$6.87 - $9.16 $71,056 - $94,741
10,343 New
10,343 $86,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $131M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.